Resistance mechanisms of tumour cells to EGFR inhibitors-Reference-Cited by-同舟云学术

Resistance mechanisms of tumour cells to EGFR inhibitors

Published:2009-05 Issue:5 Volume:11 Page:270-275
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Morgillo Floriana,Cantile Flavia,Fasano Morena,Troiani Teresa,Martinelli Erika,Ciardiello Fortunato

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-009-0354-6.pdf

Reference61 articles.

1. Bogdan S, Klambt C (2001) Epidermal growth factor receptor signaling. Curr Biol 11:292–295

2. Hirsch FR, Witta S (2005) Biomarkers for prediction of sensitivity to EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 17:118–122

3. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754

4. Liu B, Fang M, Lu Y et al (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20:1913–1922

5. Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62:3151–3158

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models;Cancer Chemotherapy and Pharmacology;2018-07-27

2. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma;Oncotarget;2016-07-13

3. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition;International Journal of Oncology;2016-01-05

4. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer;Critical Reviews in Oncology/Hematology;2016-01

5. Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer;Current Colorectal Cancer Reports;2014-06-27